Compugen (CGEN) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Compugen Reports First Quarter 2022 Results
May 16, 2022 7:00 AM EDTTriple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responsesCOM701, a unique check point inhibitor, with potential to recruit additional T cells to the TMECOM902 has the potential to be a best-in-class anti-TIGIT antibodyOn track to deliver clinical data from the cohort expansion study of COM701/nivolumab in MSS CRC in Q4 2022Enrollment continues in the Phase 1 clinical studies for COM701 and COM902Cash balance of $107 million affirms focus on capital efficiency with bold execution on Compugen's DNAM-1 axis... More
